Li Zeng

Title: The Innovative Contributions of Li Zeng in Antibody Formulations

Introduction

Li Zeng, an accomplished inventor based in Edison, NJ, has made significant strides in the field of antibody formulations. With a total of five patents under his name, his work has prominently focused on the development of stable compositions for high-concentration allotype-selected antibodies, aimed at improving medical administration techniques.

Latest Patents

One of Li Zeng's latest patents is focused on "Stable compositions of high-concentration allotype-selected antibodies for small-volume administration." This patent outlines methods, compositions, and uses for high-concentration antibody or immunoglobulin formulations intended for local administration via subcutaneous, intramuscular, or transdermal routes. The formulations are designed to be administered in volumes less than 3, 2, or even 1 ml. These compositions preferably include a high concentration formulation buffer comprising phosphate, citrate, polysorbate 80, and mannitol, optimized for a pH of about 5.2. The formulations are particularly noteworthy for containing antibodies at concentrations of 100, 150, 200, 250, or even up to 300 mg/ml. The methods to prepare these formulations utilize ultrafiltration and diafiltration techniques to concentrate the antibodies and exchange the medium for the high concentration formulation buffer. Moreover, the patent covers the application of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and nG1m1,2 antibodies, which exhibit decreased immunogenicity compared to traditional G1m1 antibodies.

Career Highlights

Li Zeng is currently associated with Immunomedics, Inc., where he continues to contribute to groundbreaking advancements in biopharmaceutical research. His commitment to innovation in antibody development is evident through his sustained contributions to the field, solidifying his reputation as a leading inventor in the area of high-concentration antibody formulations.

Collaborations

Throughout his career, Li has collaborated with esteemed colleagues including Rohini Mitra and Edmund A. Rossi. These collaborations have likely enriched his research output and contributed to the innovative solutions that have emerged from their collective expertise in the field.

Conclusion

In conclusion, Li Zeng's inventive spirit and dedication to advancing the field of antibody formulations have led to significant contributions through his patented works. As his career unfolds, his continued collaboration with fellow innovators in the biopharmaceutical industry promises further advancements in antibody therapies, paving the way for improved treatment options in medicine.